PARIS, May 15, 2014 /PRNewswire/ --
Boston Scientific Reinforces Its Commitment to Global Education and Innovation
Boston Scientific Corporation (NYSE: BSX) celebrated the opening of a new facility dedicated to endoscopy training within its Institute for Advancing Science in Paris. The ceremony included major representatives of the endoscopy medical community in Europe. Endoscopy professional training and education is now part of the multi-disciplinary programs available for European physicians within the Paris Institute.
The Institute is fully equipped with state-of-the-art technology to support integrated hands-on and didactic medical training in endoscopy. It has a broad range of endoscopes, bronchoscopes, advanced visualization systems and numerous biological and non-biological models to recreate and simulate adapted clinical conditions for training and education. Physicians will have access to a complete endoscopy lab fully equipped with fluoroscopy capabilities and simultaneous translation facilities. Boston Scientific offers a broad curriculum of training courses from basic to advanced levels in a range of specialties and techniques including Endoscopic Retrograde Cholangiopancreatography (ERCP), Endoscopic Ultrasound (EUS), cholangioscopy and Bronchial Thermoplasty (BT). The Institute in Paris reinforces the commitment that Boston Scientific has to innovation and education by offering world class training facilities designed to meet the educational needs of endoscopists, endosonographers and pulmonologists.
Over the last year, Boston Scientific trained more than 25,000 health care providers worldwide through local and regional programs, seminars, preceptorships and proctorships. In Europe alone, more than 2,500 nurses and technicians participated in more than 300 training sessions in more than 12 countries as a part of the Boston Scientific Professional Development Program. The company also unveiled several new centers of excellence. Last April, Boston Scientific hosted physicians and fellows at its third Center of Excellence Workshop at the National University Hospital in Singapore. Earlier this year, the company launched the Endoscopy Institute in Shanghai, China, which provides basic through advanced ERCP courses and fellowship training as well as a "train the trainer" program. In March 2014, seven experts in ERCP participated in the Institute's first faculty meeting and the first course took place in May. Most recently, Boston Scientific opened a training center at its Endoscopy headquarters in Marlborough, Massachusetts, including state-of-the-art equipment to facilitate education and collaboration with health care providers. In 2012, Boston Scientific became the first industry partner to commit to the American Society for Gastrointestinal Endoscopy's (ASGE) capital campaign at the Cornerstone Level for its global Institute for Training and Technology.
"The development of endoscopy training demonstrates Boston Scientific's continued commitment to providing industry-leading training and education in partnership with physicians and societies to further the practice of endoscopy," said Paraic Curtis, vice president of Endoscopy Europe Boston Scientific. "Hands-on training and peer-to-peer education are essential to maintaining good clinical practice and improving the quality of patient care. We hope that endoscopy training at the Institute for Advancing Science will become an integral part of the training continuum of endoscopists and pulmonologists across Europe."
To learn more about gastrointestinal products and procedures, please visit http://www.bostonscientific.com/endo-resources.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit http://www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, professional education and training, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
SOURCE Boston Scientific